tiprankstipranks
Trending News
More News >
Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
US Market
Advertisement

Guardian Pharmacy Services, Inc. Class A (GRDN) AI Stock Analysis

Compare
14 Followers

Top Page

GRDN

Guardian Pharmacy Services, Inc. Class A

(NYSE:GRDN)

Rating:47Neutral
Price Target:
Guardian Pharmacy Services, Inc. presents a mixed picture. Strong revenue growth and positive guidance improve the outlook, yet significant profitability and leverage challenges remain. The technical analysis signals a short-term upward trend, but valuation is difficult to assess due to missing key metrics. Overall, the stock's strengths in growth are countered by financial and valuation uncertainties, resulting in a moderate stock score.

Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)

Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model

Company DescriptionGuardian Pharmacy Services, Inc. Class A (GRDN) is a leading provider of pharmacy services specializing in long-term care and senior living communities. The company operates in the healthcare sector, offering a comprehensive range of pharmaceutical solutions tailored to meet the unique needs of its clients. GRDN's core services include medication packaging, delivery, and management, ensuring the safe and efficient dispensing of drugs to residents in various care facilities.
How the Company Makes MoneyGuardian Pharmacy Services, Inc. generates revenue primarily through the provision of pharmacy services to long-term care and senior living facilities. The company earns money by supplying medications directly to these institutions, where they are responsible for managing the pharmaceutical needs of residents. Key revenue streams include the sale of prescription drugs, consulting services for medication management, and specialized packaging solutions that ensure compliance with healthcare regulations. Significant partnerships with healthcare institutions and insurance providers also contribute to its earnings by facilitating a steady client base and enhancing service delivery. Additionally, GRDN may receive reimbursements from government programs and private insurance for medications dispensed to covered individuals.

Guardian Pharmacy Services, Inc. Class A Financial Statement Overview

Summary
Guardian Pharmacy Services, Inc. faces profitability and leverage challenges. The company has shown positive revenue growth, but operational inefficiencies have led to recent losses. The absence of equity highlights financial risks, yet stable cash flows provide some operational reassurance. Strategic adjustments are needed to improve profitability and balance sheet strength.
Income Statement
40
Negative
Gross profit margin has remained relatively stable while revenue growth has been positive over the years. However, the company faced significant challenges in the latest year, with negative EBIT and net income, highlighting operational inefficiencies and profitability issues.
Balance Sheet
30
Negative
The balance sheet shows high leverage with no stockholders' equity for the past years, indicating significant financial risk. The debt-to-equity ratio cannot be calculated due to zero equity, suggesting potential solvency concerns.
Cash Flow
55
Neutral
The company managed to maintain positive operating and free cash flows, indicating decent cash management. However, the free cash flow growth rate is inconsistent, and the reliance on cash flow to sustain operations due to negative net income is a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.33B1.23B1.05B908.91M792.07M735.96M
Gross Profit260.48M244.37M208.31M185.87M161.26M147.00M
EBITDA-41.03M-43.43M58.81M68.15M46.49M49.07M
Net Income-82.22M-87.29M23.90M35.42M16.31M19.94M
Balance Sheet
Total Assets356.33M320.81M271.17M256.11M235.85M217.87M
Cash, Cash Equivalents and Short-Term Investments18.82M4.66M752.00K607.00K15.01M6.45M
Total Debt33.70M30.13M61.00M56.81M50.43M58.84M
Total Liabilities176.66M170.83M211.31M180.19M182.53M150.80M
Stockholders Equity169.56M142.67M0.000.000.000.00
Cash Flow
Free Cash Flow37.92M41.59M56.26M31.75M49.22M44.27M
Operating Cash Flow57.66M57.96M70.82M48.52M58.50M52.61M
Investing Cash Flow-32.25M-30.41M-13.44M-17.90M-13.15M-12.18M
Financing Cash Flow-8.13M-23.64M-57.23M-45.03M-36.79M-34.26M

Guardian Pharmacy Services, Inc. Class A Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
-0.85%-23.40%
70
Outperform
$8.44B22.3711.18%2.29%14.98%
65
Neutral
$3.35B15.9612.05%0.63%4.23%
59
Neutral
$35.53B23.07-43.80%1.36%-1.94%85.70%
51
Neutral
$7.85B-0.21-41.41%2.22%22.81%-2.01%
47
Neutral
$1.67B-97.70%
43
Neutral
$378.50M-144.11%-17.10%-2720.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GRDN
Guardian Pharmacy Services, Inc. Class A
26.42
8.67
48.85%
CAH
Cardinal Health
148.78
35.89
31.79%
HSIC
Henry Schein
69.58
-0.88
-1.25%
OMI
Owens & Minor
4.90
-10.47
-68.12%
PDCO
Patterson Companies
31.33
9.29
42.15%
PBH
Prestige Consumer Healthcare
68.04
-6.05
-8.17%

Guardian Pharmacy Services, Inc. Class A Corporate Events

Business Operations and StrategyFinancial Disclosures
Guardian Pharmacy Sets 2025 Incentive Performance Targets
Neutral
Mar 28, 2025

On March 24, 2025, Guardian Pharmacy Services, Inc. announced the establishment of performance criteria and targets for its 2025 annual cash incentive awards under the 2024 Equity and Incentive Compensation Plan. The performance metrics include company revenue, adjusted EBITDA, and geographic expansion, with varying weightings. Executive officers have specific payout ranges based on achieving threshold, target, and maximum performance goals, impacting their potential earnings for the year.

Business Operations and StrategyFinancial Disclosures
Guardian Pharmacy Services Reports Strong Q4 2024 Results
Positive
Mar 3, 2025

Guardian Pharmacy Services, Inc. announced preliminary unaudited financial results for Q4 and full year 2024, showing a strong performance with a 20.5% increase in Q4 revenue driven by organic growth, acquisitions, and increased vaccinations. Despite a decrease in net income due to tax provisions and share-based compensation expenses, the company reported a 30.3% increase in adjusted EBITDA. Guardian provided 2025 guidance with expected revenue between $1.330 billion and $1.350 billion, and adjusted EBITDA between $97.0 million and $101.0 million, indicating a positive outlook for the coming year.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 11, 2025